Fig. 2
From: Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion
RSK inhibition negatively affects growth and survival of MAPK pathway-hyperactivated melanoma cells. A Cell viability (AlamarBlue assay) of melanoma cell lines from different mutational subgroups (BRAFMut, NRASMut, NF-1LOF), patient-derived melanoma short-term cultures as well as of melanocytes (NHM) as benign control cells after treatment with the RSK inhibitor PMD-026 for 72 h (N ≥ 2 with n = 3; mean ± standard deviation (SD)). Viability was normalized to solvent-treated control cells and significance determined by one-way ANOVA with subsequent Tukey’s multiple comparisons test. B, C Flow cytometric cell cycle analyses of melanoma cell lines and a melanoma patient-derived short-term culture (TüMel110) following treatment with PMD-026 or the BRAFV600E/K inhibitor vemurafenib for 3 d (n = 3; mean ± SD)